179 results on '"Ibrahim, Amna"'
Search Results
2. A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma
3. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
4. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
5. Link Between Political and Economic Stability: A Case Study of Pakistan
6. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
7. Evaluation of the efficiency of laser acupuncture in management of chronic lateral epicondylitis in adolescents
8. A rare subtype of McCune-Albright syndrome in a 5.4 years old girl: a case report and review of the literature
9. Supplementary Tables S1-S7 from An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer
10. The Contribution of Adsorbent Materials (Silica Gel and Sawdust) in Removing Water Vapor; Iraq as a Study Case
11. Angiopoietin-2 as a Marker of Retinopathy in Children and Adolescents With Sickle Cell Disease: Relation to Subclinical Atherosclerosis
12. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
13. Effect of heavy cigarette and water pipe smoking on antioxidants and lipids in Sudanese male smokers: a case-control study
14. opinions of Imad Al-Kashi in the science of meanings
15. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors
16. The beneficial effect of Adansonia digitata products success to modulate lipid profiles and inhibit LDL oxidation in-vitro: An associational study
17. U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review
18. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
19. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma
20. Effect of heavy cigarette and water pipe smoking on antioxidants and lipids in Sudanese male smokers: a case-control study.
21. Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples
22. Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.
23. An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC).
24. An FDA pooled analysis: Characteristics and outcomes of patients with nonmetastatic castration-resistant prostate cancer, based on prior history of prostatectomy and/or radiation therapy.
25. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
26. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity
27. Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies
28. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer
29. An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer
30. FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
31. Frequency and severity of ketoacidosis at diagnosis among childhood type 1 diabetes in Khartoum state, Sudan
32. FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials.
33. Metastasis free survival in older men with nonmetastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: An FDA-pooled analysis.
34. Impact of timing of antibiotic use on clinical outcomes in patients with urothelial cancer treated with immune checkpoint inhibitors (ICIs).
35. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
36. Consistency of patient versus investigator reporting of symptomatic adverse events (AEs) in international trials.
37. Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer
38. Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
39. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer
40. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
41. Impact of antibiotic use on clinical outcomes in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.
42. An FDA analysis of the association between adverse events and outcome in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.
43. Causes of patient ineligibility in clinical trials of metastatic urothelial cancer.
44. Association between past medical history (PMH) of autoimmune events and adverse events of special interest (AESI).
45. FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
46. Association between Soft Drink Consumption and Asthma among Qatari Adults
47. Empirical investigation of socially responsible investments in Pakistani firms using Carhart four factor model
48. A Neglected Case of Multifocal Liposarcoma Presented in Five Different Sites in a Syrian Woman: A case report
49. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
50. Frequency and severity of ketoacidosis at diagnosis among childhood type 1 diabetes in Khartoum state, Sudan.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.